Dapsone for Acute Ischemia Stroke Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2/PHASE3

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-07-31

Study Completion Date

2010-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of the study is to get information about the safety and efficacy of treatment with Dapsone to prevent the disability after ischemic Stroke, in patients diagnosed with anterior territory brain infarct.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study for the Use of Alteplase in Patients Who Awaken With Stroke

NCT01150266

Ischemic Stroke

WITHDRAWN PHASE1

A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke

NCT02152280

Stroke

UNKNOWN PHASE4

Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke

NCT03290560

Acute Ischemic Stroke

COMPLETED PHASE2

A Phase Ib/II in Patients With Acute Ischemic Stroke

NCT02963376

Ischemic Stroke

COMPLETED PHASE1

IMPROVE Stroke Care- Developing and Optimizing Regional Systems of Stroke Care

NCT04242784

Acute Stroke Intracranial Hemorrhages Subarachnoid Hemorrhage

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cerebrovascular diseases are the third cause of mortality around the world. Seventy-five percent of the cases correspond to ischemic stroke, and the remaining 25 % to hemorrhagic infarct. The social impact of Stroke is high as it is the first cause for disabilities. After Stroke, several mechanisms of secondary damage act to spread the damage to the surrounding tissue. Those mechanisms include: 1) Excitotoxicity after excitatory amino acids' release 2) Overproduction of free radicals 3) Exacerbated inflammatory response and 4) Apoptosis. Many neuroprotective strategies have been tested to cope with the already mentioned damaging processes with poor clinical results. Many clinical trials have failed to provide neuroprotection to patients after acute stroke. Then, the need for safe drugs with clinical efficacy to prevent Stroke disability consequences is highly recognized. Dapsone is safe and relatively free of adverse reactions, we propose a clinical trial to assess the safety and efficacy of using this drug in patients with ischemic brain stroke.

Methods: A double-blind, placebo-controlled, randomized clinical trial of dapsone is to be conducted from 2009 to 2010. Three-hundred patients with a CT or MRI documented ischemic stroke in the anterior cerebral territory are to be included. Patients with 4 to 20 points of the National Institute of Health Stroke Scale (NIHSS) will be randomly allocated to receive either a single total dose of 250 mg dapsone or placebo within the first 12 h after stroke. For the follow-up, NIHSS on days 0, 2, 7, 30, 60 and 90, modified Rankin scale (mRS) on days 0, 30, 60 and 90, and Barthel index (BI) at day 90, will be all applied. Adverse reactions will be also recorded. The Primary clinical outcome of the patients will be assessed at 90 days after stroke by obtaining the shift analysis from the baseline levels of the scales mRS and NIHSS. Secondary clinical outcome will be the BI at day 90. An interim analysis of the data will be performed when the study have recruited one-hundred patients.

Statistical analysis will be performed with the intention-to-treat approach.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebral Stroke Cerebrovascular Accident, Acute Cerebrovascular Stroke Stroke, Acute Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Patients will receive either a single total dose of 250 mg placebo IV and oral dosage

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Patients will receive either a single total dose of 250 mg placebo IV and oral dosage

Dapsone

Patients will receive either a single total dose of 250 mg IV and oral dosage

Group Type EXPERIMENTAL

Dapsone

Intervention Type DRUG

Patients will receive either a single total dose of 250 mg dapsone or placebo IV and oral dosage

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dapsone

Patients will receive either a single total dose of 250 mg dapsone or placebo IV and oral dosage

Intervention Type DRUG

Placebo

Patients will receive either a single total dose of 250 mg placebo IV and oral dosage

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

diamino-diphenyl sulfone DDS

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with the clinical diagnosis of an acute cerebrovascular event in in the anterior cerebral territory, within the last 12 hours who match the MRI or axial CT image.
* Patients with 4 o more points of the National Institute of Health Stroke Scale (NIHSS)
* Age older than 18 years, both gender
* Non acute cerebrovascular event previous
* Informed consent signed by patient or relatives

Exclusion Criteria

* Diagnosed with recurrent diseases like: heart failure; Myocardial Infarction up 8 weeks before; ventrivular arrhythmia diagnosed by ECG; Second-Degree and Third-Degree Atrioventricular Block; or Long QT Syndrome.
* Pregnancy
* Allergic reactions to sulfa medications
* Patients with kidney failure and hepatic insufficiency
* Deficiency of glucose-6-phosphate dehydrogenase diagnosed

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No